Hadassah

Hadassah Drug to Fight Fatty Liver Disease Progressing Well in US Clinical Trials

Thursday, Sep 3 2015

Clinical trials with a Hadassah-developed technology to treat fatty liver disease are moving forward in 25 medical centers, in the United States and Australia. Fatty liver disease, in its severe form—called non-alcoholic steatohepatitis (NASH)—can lead to cirrhosis and liver cancer and there are currently no other treatments available.

Among the US test sites are the Cleveland Clinic (Ohio), Duke Liver Center (Durham, NC), Baylor St. Luke's Medical Center (Houston, Tex), and University of Virginia (Charlottesville). The Australian sites include Westmead Hospital (Sydney) and The Alfred (Melbourne).

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product, being referred to as IMM-124E. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron. See http://www.hadassah.org/news-stories/fda-grants-approval-for-us.html

Immuron has also announced that it is beginning a United States Investor Roadshow, where it will showcase its technology platform and profile to US investment groups. The company reports that its clinical trials “are progressing well” and that “a recent Deutsche Bank review of the NASH market suggests that there is a worldwide market for NASH of between $35-40 billion.” The company further explains that “the high prevalence of Type 2 diabetes and obesity, which leads to NASH and other non-alcoholic fatty liver diseases, boosts the prevalence of NASH and its market growth.”

View the Roadshow presentation: http://www.immuron.com/index.php/download_file/-/view/142/

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Apr 18 2019

Hadassah Cardiac Specialist Recognized for Lifetime Achievement

Congratulations to Hadassah Medical Organization Prof. Emeritus Andre Keren upon receiving the Lifetime Achievement Award from the European Society of Cardiology’s Working Group on Myocardial and Pericardial Diseases.

READ MORE ›
alt_text

Thursday, Apr 18 2019

Hadassah’s Pollin Center Celebrates Five Years of Women’s Wellness Achievements

Longing to commemorate the early death of her daughter from cardiovascular disease, Irene Pollin established the Linda Joy Pollin Cardiovascular Wellness Center for Women at Hadassah Hospital Ein Kerem in 2013.

READ MORE ›
alt_text

Thursday, Apr 18 2019

Pre-clinical Study by Hadassah Neurologists Sheds Light on Major Player in Alzheimer’s Disease

While scientists know a vast amount about what can go wrong in a brain afflicted with Alzheimer’s disease, they also know very little about how our brains protect themselves from such injuries, reports Prof. Tamir Ben-Hur, head of the Division of Clinical Neurosciences at the Hadassah Medical Organization.

READ MORE ›
alt_text

Wednesday, Apr 17 2019

First in Israel: Hadasit Launches Medical Startup Accelerator with IBM

Hadasit, the Hadassah Medical Organization’s technology transfer company, has launched Israel’s first biotechnology hub within a medical center.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More